



Diagnosis and Control of African Swine Fever Virus (ASFV) Infection

Guest Editors:

Dr. Marisa Arias

European Union Reference
Laboratory for ASF and FAO
Reference Centre for ASF, Centro
de Investigación en Sanidad
Animal CISA-INIA/CSIC,
Valdeolmos, 28130 Madrid, Spain

Dr. Carmina Gallardo

European Union Reference
Laboratory for ASF and FAO
Reference Centre for ASF, Centro
de Investigación en Sanidad
Animal CISA-INIA/CSIC,
Valdeolmos, 28130 Madrid, Spain

Deadline for manuscript
submissions:

15 July 2024

Message from the Guest Editors

African swine fever (ASF) is currently the most threatening disease in domestic and wild pigs worldwide for which there is no commercial vaccine available. The presence of ASF on five continents, including large parts of Asia, makes ASF the worst livestock pandemic of this century. The causal agent, the African swine fever virus (ASFV), is a large and highly complex virus that affects both domestic and wild pigs, such as European and African wild pigs, making it difficult to eradicate in endemic areas with the coexistence of circulating viruses of different virulence. The purpose of this special issue of *Vaccines* is to update knowledge and research on important aspects of the disease related to virus infection, disease dynamics, diagnostic tools, and control strategies. Particular emphasis will be placed on research focused on studies with new vaccine candidates, including the elucidation of vaccine control strategies.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious
Diseases, College of Veterinary
Medicine, University of Georgia,
Athens, GA 30602-7387, USA

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Author Benefits

Open Access: free for readers, with **article processing charges (APC)** paid by authors or their institutions.

High Visibility: indexed within **Scopus**, **SCIE (Web of Science)**, **PubMed**, **PMC**, **Embase**, **CAPus / SciFinder**, and **other databases**.

Journal Rank: JCR - Q1 (*Immunology*) / CiteScore - Q1 (*Pharmacology (medical)*)

Contact Us

Vaccines Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/vaccines
vaccines@mdpi.com